Knut Engels
YOU?
Author Swipe
View article: Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX)
Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX) Open
Denosumab as part of neoadjuvant therapy, although not improving the pCR rate, significantly reduced the risk of distant relapses. Other long-term outcome parameters did not differ between the treatment arms. TNBC patients, especially when…
View article: Supplementary Figure S1 from An Analysis of <i>PIK3CA</i> Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Supplementary Figure S1 from An Analysis of <i>PIK3CA</i> Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials Open
PIKCA mutation frequency in study
View article: Supplementary Table S1 from An Analysis of <i>PIK3CA</i> Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Supplementary Table S1 from An Analysis of <i>PIK3CA</i> Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials Open
Distribution of PIK3CA mutations status on any, exon and hotspot level in the trial cohort (A) according to molecular subtype as well as (B) in the HER2pos cohort, stratified by HR status.
View article: Supplementary Figure S2 from An Analysis of <i>PIK3CA</i> Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Supplementary Figure S2 from An Analysis of <i>PIK3CA</i> Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials Open
Survival analysis (DFS and OS) in the full cohort using Kaplan-Meier plots with log rank tests for statistical evaluation stratified by PIKC mutations status.
View article: Data from An Analysis of <i>PIK3CA</i> Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Data from An Analysis of <i>PIK3CA</i> Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials Open
Purpose:The PI3K signaling pathway is frequently dysregulated in breast cancer, and mutations in PIK3CA are relevant for therapy resistance in HER2-positive (HER2pos) breast cancer. Mutations in exons 9 or 20 may have different impacts on …
View article: Data from An Analysis of <i>PIK3CA</i> Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Data from An Analysis of <i>PIK3CA</i> Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials Open
Purpose:The PI3K signaling pathway is frequently dysregulated in breast cancer, and mutations in PIK3CA are relevant for therapy resistance in HER2-positive (HER2pos) breast cancer. Mutations in exons 9 or 20 may have different impacts on …
View article: Supplementary Table S4 from An Analysis of <i>PIK3CA</i> Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Supplementary Table S4 from An Analysis of <i>PIK3CA</i> Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials Open
Logistic regression model using PIK3CA mutation level status predicting pCR as binary endpoint in molecular subtypes and in HER2pos cohort stratified by HR status.
View article: Supplementary Table S3 from An Analysis of <i>PIK3CA</i> Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Supplementary Table S3 from An Analysis of <i>PIK3CA</i> Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials Open
pCR rates of HER2pos subgroup stratified by anti-HER2 treatment regimes
View article: Supplementary Figure S1 from An Analysis of <i>PIK3CA</i> Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Supplementary Figure S1 from An Analysis of <i>PIK3CA</i> Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials Open
PIKCA mutation frequency in study
View article: Supplementary Table S2 from An Analysis of <i>PIK3CA</i> Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Supplementary Table S2 from An Analysis of <i>PIK3CA</i> Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials Open
pCR rates in molecular subgroups
View article: Supplementary Table S1 from An Analysis of <i>PIK3CA</i> Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Supplementary Table S1 from An Analysis of <i>PIK3CA</i> Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials Open
Distribution of PIK3CA mutations status on any, exon and hotspot level in the trial cohort (A) according to molecular subtype as well as (B) in the HER2pos cohort, stratified by HR status.
View article: Supplementary Table S4 from An Analysis of <i>PIK3CA</i> Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Supplementary Table S4 from An Analysis of <i>PIK3CA</i> Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials Open
Logistic regression model using PIK3CA mutation level status predicting pCR as binary endpoint in molecular subtypes and in HER2pos cohort stratified by HR status.
View article: Supplementary Table S3 from An Analysis of <i>PIK3CA</i> Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Supplementary Table S3 from An Analysis of <i>PIK3CA</i> Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials Open
pCR rates of HER2pos subgroup stratified by anti-HER2 treatment regimes
View article: Supplementary Table S2 from An Analysis of <i>PIK3CA</i> Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Supplementary Table S2 from An Analysis of <i>PIK3CA</i> Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials Open
pCR rates in molecular subgroups
View article: Supplementary Figure S2 from An Analysis of <i>PIK3CA</i> Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Supplementary Figure S2 from An Analysis of <i>PIK3CA</i> Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials Open
Survival analysis (DFS and OS) in the full cohort using Kaplan-Meier plots with log rank tests for statistical evaluation stratified by PIKC mutations status.
View article: Data from Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor
Data from Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor Open
Purpose: This study aimed to evaluate a modified EPclin test (mEPclin), a combination of EndoPredict (EP) score, post-neoadjuvant pathologic tumor size and nodal status, for predicting the risk of distance recurrence after neoadjuvant chem…
View article: Figure S8 from A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial
Figure S8 from A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial Open
Hypoxia signature and response by treatment arm
View article: Figure S6 from A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial
Figure S6 from A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial Open
Correlation of proliferation signature and histological grade
View article: Figure S5 from A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial
Figure S5 from A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial Open
Comparison of gene signature detection in High Quality and Low Quality Samples
View article: Figure S1 from A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial
Figure S1 from A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial Open
Flow of samples through the study (CONSORT).
View article: Figure S1 from A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial
Figure S1 from A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial Open
Flow of samples through the study (CONSORT).
View article: Supplementary Figures and Tables from Poor Outcome in Estrogen Receptor–Positive Breast Cancers Predicted by Loss of <i>Plexin B1</i>
Supplementary Figures and Tables from Poor Outcome in Estrogen Receptor–Positive Breast Cancers Predicted by Loss of <i>Plexin B1</i> Open
8 Supplementary Figures and 2 Supplementary Tables
View article: Figure S7 from A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial
Figure S7 from A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial Open
Poor detection of NDRG1 expression signal in TMA analysis
View article: Online-Only Tables: 1 and Online-Only Figures: 2 from Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor
Online-Only Tables: 1 and Online-Only Figures: 2 from Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor Open
Supplementary Table 1: Multivariate analysis of the continuous mEPclin and CPS-EG scores including Ki67 status according to DFS Supplementary Figures
View article: Data from A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial
Data from A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial Open
Purpose:In breast cancer, bevacizumab increased pCR rate but not long-term survival and no predictive markers are available to identify patients with long-term benefit from the drug.Experimental Design:We profiled 289 pretherapeutic formal…
View article: Figure S3 from A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial
Figure S3 from A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial Open
Correlation of Affymetrix microarray expression data and IHC scoring of three genes in independent TNBC dataset
View article: Supplementary Figures and Tables from Poor Outcome in Estrogen Receptor–Positive Breast Cancers Predicted by Loss of <i>Plexin B1</i>
Supplementary Figures and Tables from Poor Outcome in Estrogen Receptor–Positive Breast Cancers Predicted by Loss of <i>Plexin B1</i> Open
8 Supplementary Figures and 2 Supplementary Tables
View article: Figure S2 from A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial
Figure S2 from A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial Open
Immunohistochemical validation of hypoxia signature
View article: Figure S5 from A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial
Figure S5 from A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial Open
Comparison of gene signature detection in High Quality and Low Quality Samples